All Stories

  1. P2 purinergic receptors in systemic lupus erythematosus: from experimental findings to therapeutic perspectives

    Article • Current Opinion in Immunology, June 2026, Elsevier

    yves Renaudineau

  2. Cell-specific epigenome-wide DNA methylation in peripheral CD4(+) lymphocytes from patients with primary biliary cholangitis

    Article • Journal of Translational Autoimmunity, December 2025, Elsevier

    yves Renaudineau

  3. Joint Tissues: Convergence and Divergence of the Pathogenetic Mechanisms of Rheumatoid Arthritis and Osteoarthritis

    Article • International Journal of Molecular Sciences, September 2025, MDPI AG

    yves Renaudineau

  4. Evaluation of a Gel Loaded With M101 on Bone and Peri‐Implantitis Healing: An Experimental In Vivo Study

    Article • Clinical Oral Implants Research, August 2025, Wiley

    yves Renaudineau

  5. Urinary soluble CD163 is useful to predict lupus nephritis activity and to monitor standard-of-care therapy response

    Article • Rheumatology, August 2025, Oxford University Press (OUP)

    yves Renaudineau

  6. Common Toll-like receptor 7 variants define disease risk and phenotypes in juvenile-onset systemic lupus erythematosus

    Article • Journal of Autoimmunity, July 2025, Elsevier

    yves Renaudineau

  7. Across ancestries, HLA-B∗08:01∼DRB1∗03:01 (DR3) and HLA-DQA∗01:02 (DR2) increase the risk to develop juvenile-onset systemic lupus erythematosus through low complement C4 levels

    Article • Journal of Translational Autoimmunity, June 2025, Elsevier

    yves Renaudineau

  8. Interferon-γ release assay as an emergent powerful biomarker in systemic lupus erythematosus

    Article • Rheumatology, May 2025, Oxford University Press (OUP)

    yves Renaudineau

  9. Triggering role of some environmental and individual factors in provoking rheumatoid arthritis and joint symptoms at preclinical stages of the disease

    Article • Kazan medical journal, December 2024, ECO-Vector LLC

    yves Renaudineau

  10. Urinary soluble CD163 is useful as “liquid biopsy” marker in lupus nephritis at both diagnosis and follow-up to predict impending flares

    Article • Journal of Translational Autoimmunity, December 2024, Elsevier

    yves Renaudineau

  11. Quantification of C1 inhibitor activity using a chromogenic automated assay: analytical and clinical performances

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), June 2024, De Gruyter

    yves Renaudineau

  12. Editorial from the new editor-in-chief

    Article • Journal of Translational Autoimmunity, June 2024, Elsevier

    yves Renaudineau

  13. At Early Rheumatoid Arthritis Stage, the Infectious Spectrum Is Driven by Non-Familial Factors and Anti-CCP Immunization

    Article • Journal of Clinical Medicine, May 2024, MDPI AG

    yves Renaudineau

  14. Blocking Orai1 constitutive activity inhibits B-cell cancer migration and synergistically acts with drugs to reduce B-CLL cell survival

    Article • European Journal of Pharmacology, May 2024, Elsevier

    yves Renaudineau

  15. Type I interferon associated epistasis may contribute to early disease-onset and high disease activity in juvenile-onset lupus

    Article • Clinical Immunology, May 2024, Elsevier

    yves Renaudineau

  16. Not just another klass (JAK) of inhibitors for allergies

    Article • Journal of Allergy and Hypersensitivity Diseases, January 2024, Elsevier

    yves Renaudineau

  17. Orai1 Ca2+ channel modulators as therapeutic tools for treating cancer: Emerging evidence!

    Article • Biochemical Pharmacology, January 2024, Elsevier

    yves Renaudineau

  18. Blocking Orai1 constitutive activity inhibits B-cell cancer migration and synergistically acts with drugs to reduce B-CLL cell survival

    Article • December 2023, Cold Spring Harbor Laboratory Press

    yves Renaudineau

  19. Low performance of interferon gamma release assay Quantiferon-TB gold coupled or not with Pst1/3/lipoglycan humoral detection to predict Mycobacterium tuberculosis complex disease in a low-burden area

    Article • Tuberculosis, December 2023, Elsevier

    yves Renaudineau

  20. Impact of imlifidase treatment on immunoglobulins in an HLA-hypersensitized lupus nephritis patient with anti-SSA/SSB antibodies after kidney transplantation: A case report

    Article • Journal of Translational Autoimmunity, December 2023, Elsevier

    yves Renaudineau

  21. Predictive risk factors before the onset of familial rheumatoid arthritis: the Tatarstan cohort study

    Article • Frontiers in Medicine, October 2023, Frontiers

    yves Renaudineau

  22. Lupus Nephritis Risk Factors and Biomarkers: An Update

    Article • International Journal of Molecular Sciences, September 2023, MDPI AG

    yves Renaudineau

  23. Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases

    Article • International Immunopharmacology, July 2023, Elsevier

    yves Renaudineau

  24. JAK inhibition for CD3− CD4+ lymphocytic-variant hypereosinophilic syndrome

    Article • Clinical Immunology, June 2023, Elsevier

    yves Renaudineau

  25. Characteristics of the (Auto)Reactive T Cells in Rheumatoid Arthritis According to the Immune Epitope Database

    Article • International Journal of Molecular Sciences, February 2023, MDPI AG

    yves Renaudineau

  26. Glucocorticoids selectively affect the memory T cell response to SARS-Cov2 spike in vaccinated and post-infected patients with systemic lupus erythematosus

    Article • Journal of Translational Autoimmunity, January 2023, Elsevier

    yves Renaudineau

  27. Immunological and translational key challenges in systemic lupus erythematosus: A symposium update

    Article • Journal of Translational Autoimmunity, January 2023, Elsevier

    yves Renaudineau

  28. Cerebrospinal fluid YKL‐40 level evolution is associated with autoimmune encephalitis remission

    Article • Clinical & Translational Immunology, January 2023, Wiley

    yves Renaudineau

  29. Glucocorticoid use as a cause of non-cellular immune response to SARS-Cov2 Spike in patients with immune system diseases

    Article • Journal of Autoimmunity, December 2022, Elsevier

    yves Renaudineau

  30. Anti-Citrullinated Peptide Antibodies Control Oral Porphyromonas and Aggregatibacter species in Patients with Rheumatoid Arthritis

    Article • International Journal of Molecular Sciences, October 2022, MDPI AG

    yves Renaudineau

  31. Apolipoprotein-A-I for severe COVID-19-induced hyperinflammatory states: A prospective case study

    Article • Frontiers in Pharmacology, September 2022, Frontiers

    yves Renaudineau

  32. The oxygen carrier M101 alleviates complement activation, which may be beneficial for donor organ preservation

    Article • Frontiers in Immunology, September 2022, Frontiers

    yves Renaudineau

  33. Editorial: Epigenetic aspects of autoimmune diseases

    Article • Frontiers in Cell and Developmental Biology, August 2022, Frontiers

    yves Renaudineau

  34. Kappa-index: Real-life evaluation of a new tool for multiple sclerosis diagnosis

    Article • Clinical Immunology, August 2022, Elsevier

    yves Renaudineau

  35. Myositis-specific autoantibodies in clinical practice: Improving the performance of the immunodot

    Article • Seminars in Arthritis and Rheumatism, August 2022, Elsevier

    yves Renaudineau

  36. Interplay of Environmental, Individual and Genetic Factors in Rheumatoid Arthritis Provocation

    Article • International Journal of Molecular Sciences, July 2022, MDPI AG

    yves Renaudineau

  37. Safety and pharmacokinetics of Roscovitine (Seliciclib) in cystic fibrosis patients chronically infected with Pseudomonas aeruginosa, a randomized, placebo-controlled study

    Article • Journal of Cystic Fibrosis, May 2022, Elsevier

    yves Renaudineau

  38. Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response

    Article • Clinical Immunology, April 2022, Elsevier

    yves Renaudineau

  39. Possible mechanism of the implementing the trigger role of air pollution in rheumatoid arthritis (preliminary data)

    Article • Hygiene and Sanitation, March 2022, Federal Scientific Center for Hygiene F.F.Erisman

    yves Renaudineau

  40. Long non-coding RNA Xist contribution in systemic lupus erythematosus and rheumatoid arthritis

    Article • Clinical Immunology, March 2022, Elsevier

    yves Renaudineau

  41. Altered DNA methylation pattern characterizes the peripheral immune cells of patients with autoimmune hepatitis

    Article • Liver International, February 2022, Wiley

    yves Renaudineau

  42. Lupus band test can be used in combination with anti-chromatin antibodies and complement analysis to predict transition from cutaneous to systemic lupus

    Article • Clinical Immunology, January 2022, Elsevier

    yves Renaudineau

  43. Provocation of oxidative stress by heavy metals as a possible trigger factor in the development of rheumatoid arthritis

    Article • Molekulyarnaya Meditsina (Molecular medicine), January 2022, Russkiy Vrach Publishing House

    yves Renaudineau

  44. SARS-Cov2 acute and post-active infection in the context of autoimmune and chronic inflammatory diseases

    Article • Journal of Translational Autoimmunity, January 2022, Elsevier

    yves Renaudineau

  45. Editorial: Role of Macrophage MicroRNAs in Inflammatory Diseases and Cancer

    Article • Frontiers in Immunology, September 2021, Frontiers

    yves Renaudineau

  46. Combining multi-antigenic immunodot with indirect immunofluorescence on HEp-2 cells improves the diagnosis of systemic sclerosis

    Article • Clinical Immunology, August 2021, Elsevier

    yves Renaudineau

  47. Identification of altered cell signaling pathways using proteomic profiling in stable and progressive chronic lymphocytic leukemia

    Article • Journal of Leukocyte Biology, July 2021, Wiley

    yves Renaudineau

  48. A Proinflammatory Cytokine Network Profile in Th1/Type 1 Effector B Cells Delineates a Common Group of Patients in Four Systemic Autoimmune Diseases

    Article • Arthritis & Rheumatology, July 2021, Wiley

    yves Renaudineau

  49. Altered DNA methylation pattern characterizes the peripheral immune cells of patients with autoimmune hepatitis

    Article • July 2021, Cold Spring Harbor Laboratory Press

    yves Renaudineau

  50. Tocilizumab controls bone turnover in early polymyalgia rheumatica

    Article • Joint Bone Spine, May 2021, Elsevier

    yves Renaudineau

  51. Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases

    Article • Arthritis & Rheumatology, April 2021, Wiley

    yves Renaudineau

  52. Inflammatory Markers are Quickly Improved by Tocilizumab in Early Polymyalgia Rheumatica and Might Predict Early Response to Interleukin-6 Blockade

    Article • Rheumatology and Therapy, March 2021, Springer Science + Business Media

    yves Renaudineau

  53. An elevated polyclonal free light chain level reflects a strong interferon signature in patients with systemic autoimmune diseases

    Article • Journal of Translational Autoimmunity, January 2021, Elsevier

    yves Renaudineau

  54. Causal risk and protective factors in rheumatoid arthritis: A genetic update

    Article • Journal of Translational Autoimmunity, January 2021, Elsevier

    yves Renaudineau

  55. Antiphospholipid autoantibody detection is important in all patients with systemic autoimmune diseases

    Article • Journal of Autoimmunity, December 2020, Elsevier

    yves Renaudineau

  56. CD5 and B lymphocyte responses: multifaceted effects through multitudes of pathways and channels

    Article • Cellular and Molecular Immunology, July 2020, Springer Science + Business Media

    yves Renaudineau

  57. Évaluation de la taille des glandes salivaires majeures dans le syndrome de Gougerot-Sjögren primitif : comparaison de l’examen clinique et de l’échographie

    Article • Revue du Rhumatisme, July 2020, Elsevier

    yves Renaudineau

  58. Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases

    Article • February 2020, Cold Spring Harbor Laboratory Press

    yves Renaudineau

  59. Epigenetics in Primary Sjögren’s Syndrome

    Article • January 2020, Springer Science + Business Media

    yves Renaudineau

  60. Linking genetic variation with epigenetic profiles in Sjögren's syndrome

    Article • Clinical Immunology, January 2020, Elsevier

    yves Renaudineau

  61. JAK Inhibitors and Oxidative Stress Control

    Article • Frontiers in Immunology, December 2019, Frontiers

    yves Renaudineau

  62. Assessment of major salivary gland size in primary Sjögren's syndrome: Comparison between clinical examination and ultrasonography

    Article • Joint Bone Spine, October 2019, Elsevier

    yves Renaudineau

  63. Epigenetic Modifications in Generalized Autoimmune Epithelitis: Sjögren’s Syndrome and Primary Biliary Cholangitis

    Article • Epigenomes, August 2019, MDPI AG

    yves Renaudineau

  64. News and meta-analysis regarding anti-Beta 2 glycoprotein I antibodies and their determination

    Article • Clinical Immunology, August 2019, Elsevier

    yves Renaudineau

  65. Innate B Cells: the Archetype of Protective Immune Cells

    Article • Clinical Reviews in Allergy & Immunology, June 2019, Springer Science + Business Media

    yves Renaudineau

  66. JAK Inhibitors Suppress Innate Epigenetic Reprogramming: a Promise for Patients with Sjögren’s Syndrome

    Article • Clinical Reviews in Allergy & Immunology, June 2019, Springer Science + Business Media

    yves Renaudineau

  67. The Innate Part of the Adaptive Immune System

    Article • Clinical Reviews in Allergy & Immunology, June 2019, Springer Science + Business Media

    yves Renaudineau

  68. Complement System: a Neglected Pathway in Immunotherapy

    Article • Clinical Reviews in Allergy & Immunology, May 2019, Springer Science + Business Media

    yves Renaudineau

  69. Toll-Like Receptors, Infections, and Rheumatoid Arthritis

    Article • Clinical Reviews in Allergy & Immunology, May 2019, Springer Science + Business Media

    yves Renaudineau

  70. STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia

    Article • Journal for ImmunoTherapy of Cancer, April 2019, Springer Science + Business Media

    yves Renaudineau

  71. Editorial: Shaping of Human Immune System and Metabolic Processes by Viruses and Microorganisms

    Article • Frontiers in Microbiology, April 2019, Frontiers

    yves Renaudineau

  72. Apoptotic resistance in chronic lymphocytic leukemia and therapeutic perspectives

    Article • Critical Reviews in Clinical Laboratory Sciences, April 2019, Taylor & Francis

    yves Renaudineau, Dr Wesley H Brooks

  73. Psychological stress and rheumatoid arthritis – interference of pathogenetic mechanisms

    Article • Rheumatology Science and Practice, March 2019, IMA Press, LLC

    yves Renaudineau

  74. In seroconverted rheumatoid arthritis patients a multi-reactive anti-herpes IgM profile is associated with disease activity

    Article • Clinical Immunology, March 2019, Elsevier

    yves Renaudineau

  75. Peripheral-blood b-cell subset disturbances in inflammatory joint diseases induced by Tropheryma whipplei

    Article • PLOS One, February 2019, PLOS

    yves Renaudineau

  76. Rapid and complete response to idelalisib in a case of Richter syndrome

    Article • OncoTargets and Therapy, February 2019, Dove Medical Press

    yves Renaudineau

  77. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia

    Article • Journal for ImmunoTherapy of Cancer, January 2019, Springer Science + Business Media

    yves Renaudineau

  78. A Pathogenic Cytokine Network Is Associated with Pro-Inflammatory B Cells in Systemic Lupus Erythematosus Patients

    Article • SSRN Electronic Journal, January 2019, Elsevier

    yves Renaudineau

  79. Microbiota analysis in rheumatoid arthritis: News and perspectives

    Article • Clinical Microbiology and Infectious Diseases, January 2019, Open Access Text Pvt, Ltd.

    yves Renaudineau

  80. The regulatory capacity of B cells directs the aggressiveness of CLL

    Article • OncoImmunology, December 2018, Taylor & Francis

    yves Renaudineau

  81. Prevalence and Incidence of Upper Respiratory Tract Infection Events Are Elevated Prior to the Development of Rheumatoid Arthritis in First-Degree Relatives

    Article • Frontiers in Immunology, November 2018, Frontiers

    yves Renaudineau

  82. Thrombotic risk assessment and analytical performance of the chemiluminescent analyzer IDS-iSYS for the detection of anti-cardiolipin and anti-beta 2 glycoprotein I autoantibodies

    Article • Clinical Immunology, September 2018, Elsevier

    yves Renaudineau

  83. Resistance to complement activation, cell membrane hypersialylation and relapses in chronic lymphocytic leukemia patients treated with rituximab and chemotherapy

    Article • Oncotarget, June 2018, Impact Journals, LLC

    yves Renaudineau

  84. Épigénome et syndrome de Gougerot-Sjögren

    Article • La Revue de Médecine Interne, May 2018, Elsevier

    yves Renaudineau

  85. DNA demethylation marks in chronic lymphocytic leukemia: it is time to let the cat out of the bag

    Article • Future Science OA, February 2018, Future Science

    yves Renaudineau

  86. Clinical Characteristics of Pruritus in Systemic Sclerosis Vary According to the Autoimmune Subtype

    Article • Acta Dermato-Venereologica, January 2018, Acta Dermato-Venereologica

    yves Renaudineau

  87. Associations between Viral Infection History Symptoms, Granulocyte Reactive Oxygen Species Activity, and Active Rheumatoid Arthritis Disease in Untreated Women at Onset: Results from a Longitudinal Cohort Study of Tatarstan Women

    Article • Frontiers in Immunology, December 2017, Frontiers

    yves Renaudineau

  88. Comparison of 2002 AECG and 2016 ACR/EULAR classification criteria and added value of salivary gland ultrasonography in a patient cohort with suspected primary Sjögren’s syndrome

    Article • December 2017, Springer Science + Business Media

    yves Renaudineau

  89. Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion

    Article • Clinical Epigenetics, November 2017, Springer Science + Business Media

    yves Renaudineau

  90. Alterations in DNA methylation/demethylation intermediates predict clinical outcome in chronic lymphocytic leukemia

    Article • Oncotarget, August 2017, Impact Journals, LLC

    yves Renaudineau

  91. Constitutive calcium entry and cancer: updated views and insights

    Article • European Biophysics Journal, May 2017, Springer Science + Business Media

    yves Renaudineau

  92. Calcium Signaling: From Normal B Cell Development to Tolerance Breakdown and Autoimmunity.

    Article • Clinical Reviews in Allergy & Immunology, May 2017, Springer Science + Business Media

    yves Renaudineau

  93. Dysregulated Lymphoid Cell Populations in Mouse Models of Systemic Lupus Erythematosus

    Article • Clinical Reviews in Allergy & Immunology, May 2017, Springer Science + Business Media

    yves Renaudineau

  94. Immunophenotyping As a New Tool for Classification and Monitoring of Systemic Autoimmune Diseases

    Article • Clinical Reviews in Allergy & Immunology, May 2017, Springer Science + Business Media

    yves Renaudineau

  95. Memory B Cells and Response to Abatacept in Rheumatoid Arthritis

    Article • Clinical Reviews in Allergy & Immunology, May 2017, Springer Science + Business Media

    yves Renaudineau

  96. Intracellular B Lymphocyte Signalling and the Regulation of Humoral Immunity and Autoimmunity

    Article • Clinical Reviews in Allergy & Immunology, April 2017, Springer Science + Business Media

    yves Renaudineau

  97. Correction of abnormal B-cell subset distribution by interleukin-6 receptor blockade in polymyalgia rheumatica

    Article • Rheumatology, April 2017, Oxford University Press (OUP)

    yves Renaudineau

  98. Molecular Dynamics Simulations of Membrane-Bound STIM1 to Investigate Conformational Changes during STIM1 Activation upon Calcium Release

    Article • Journal of Chemical Information and Modeling, February 2017, American Chemical Society (ACS)

    yves Renaudineau

  99. Cell-specific epigenome-wide DNA methylation profile in long-term cultured minor salivary gland epithelial cells from patients with Sjögren's syndrome

    Article • Annals of the Rheumatic Diseases, January 2017, BMJ

    yves Renaudineau

  100. Isolated Cardiac Richter Syndrome: a Case Report

    Article • Annals of Hematology, October 2016, Springer Science + Business Media

    yves Renaudineau

  101. DNA methylation signatures in Sjögren syndrome

    Article • Nature Reviews Rheumatology, September 2016, Springer Science + Business Media

    yves Renaudineau

  102. How Rheumatoid Arthritis Can Result from Provocation of the Immune System by Microorganisms and Viruses

    Article • Frontiers in Microbiology, August 2016, Frontiers

    yves Renaudineau

  103. CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes

    Article • Cellular and Molecular Immunology, August 2016, Springer Science + Business Media

    yves Renaudineau

  104. Lymphocyte Disturbances in Primary Antiphospholipid Syndrome and Application to Venous Thromboembolism Follow-Up

    Article • Clinical Reviews in Allergy & Immunology, June 2016, Springer Science + Business Media

    yves Renaudineau

  105. Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises

    Article • Immunotherapy, May 2016, Future Medicine

    yves Renaudineau

  106. Defective DNA methylation in salivary gland epithelial acini from patients with Sjögren's syndrome is associated with SSB gene expression, anti-SSB/LA detection, and lymphocyte infiltration

    Article • Journal of Autoimmunity, April 2016, Elsevier

    yves Renaudineau

  107. Regulatory B lymphocyte functions should be considered in chronic lymphocytic leukemia

    Article • OncoImmunology, March 2016, Taylor & Francis

    yves Renaudineau

  108. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study

    Article • Annals of the Rheumatic Diseases, February 2016, BMJ

    yves Renaudineau

  109. B lymphocytes of chronic lymphocytic leukemia, regulatory B lymphocytes which ignore?

    Article • Hématologie, January 2016, John Libbey Eurotext

    yves Renaudineau

  110. Abatacept efficacy in rheumatoid arthritis is dependent upon baseline blood B-cell levels

    Article • Rheumatology, December 2015, Oxford University Press (OUP)

    yves Renaudineau

  111. An in silico Approach Reveals Associations between Genetic and Epigenetic Factors within Regulatory Elements in B Cells from Primary Sjögren’s Syndrome Patients

    Article • Frontiers in Immunology, August 2015, Frontiers

    yves Renaudineau

  112. Anti-alpha-actinin antibodies are part of the anti-cell membrane antibody spectrum that characterize patients with lupus nephritis

    Article • Journal of Autoimmunity, July 2015, Elsevier

    yves Renaudineau

  113. AB0305 Pre-Treatment B-Cell Lymphopenia is Associated with a Low Response Rate to Abatacept in Patients with Rheumatoid Arthritis

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    yves Renaudineau

  114. Au-delà de nos gènes: la révolution de l’épigénétique

    Article • Revue Francophone des Laboratoires, June 2015, Elsevier

    yves Renaudineau

  115. FRI0280 Efficacy and Safety of Tocilizumab as First Line Therapy in Patients with Recent Polymyalgia Rheumatica (PMR): Results of the First Longitudinal Prospective Study (Tenor)

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    yves Renaudineau

  116. FRI0404 Disturbances of T and B Cell Homeostasis Characterized Primary Antiphospholipid Patients During their Follow-Up of Venous Thromboembolism

    Article • Annals of the Rheumatic Diseases, June 2015, BMJ

    yves Renaudineau

  117. Épigénétique et médecine prédictive

    Article • Revue Francophone des Laboratoires, June 2015, Elsevier

    yves Renaudineau

  118. Ofatumumab capacity to deplete B cells from chronic lymphocytic leukaemia is affected by C4 complement exhaustion

    Article • European Journal Of Haematology, May 2015, Wiley

    yves Renaudineau

  119. Genetics and Epigenetics of Autoimmune Diseases

    Article • May 2015, Wiley

    yves Renaudineau

  120. Human Endogenous Retrovirus Group E and Its Involvement in Diseases

    Article • Viruses, March 2015, MDPI AG

    yves Renaudineau

  121. Epigenetics and autoimmune diseases: the X chromosome-nucleolus nexus

    Article • Frontiers in Genetics, February 2015, Frontiers

    yves Renaudineau

  122. A1.9 Among patients with venous thrombo-embolism, B cell subset disturbances characterise those with primary antiphospholipid syndrome

    Article • Annals of the Rheumatic Diseases, February 2015, BMJ

    yves Renaudineau

  123. A7.15 B-cell lymphopenia is associated with a low response rate to abatacept in patients with rheumatoid arthritis

    Article • Annals of the Rheumatic Diseases, February 2015, BMJ

    yves Renaudineau

  124. Annexin A2 autoantibodies in thrombosis and autoimmune diseases

    Article • Thrombosis Research, February 2015, Elsevier

    yves Renaudineau

  125. Calcium signaling and cell fate: how can Ca2+ signals contribute to wrong decisions for Chronic Lymphocytic Leukemic B lymphocyte outcome?

    Article • The International Journal of Developmental Biology, January 2015, UBC Press

    yves Renaudineau

  126. Endothelial Cell Autoreactivity and Infection

    Article • January 2015, Elsevier

    yves Renaudineau

  127. How the Environment Influences Epigenetics, DNA Methylation, and Autoimmune Diseases

    Article • January 2015, Elsevier

    yves Renaudineau

  128. Génomique, épigénétique et pathologies

    Article • Option/Bio, December 2014, Elsevier

    yves Renaudineau

  129. Anti-SLA/LP alone or in combination with anti-Ro52 and fine specificity of anti-Ro52 antibodies in patients with autoimmune hepatitis

    Article • Liver International, August 2014, Wiley

    yves Renaudineau, Professor DIMITRIOS P BOGDANOS

  130. The Differential Diagnosis of Dry Eyes, Dry Mouth, and Parotidomegaly: A Comprehensive Review

    Article • Clinical Reviews in Allergy & Immunology, June 2014, Springer Science + Business Media

    yves Renaudineau

  131. Salivary gland ultrasonography improves the diagnostic performance of the 2012 American College of Rheumatology classification criteria for Sjogren's syndrome

    Article • Rheumatology, April 2014, Oxford University Press (OUP)

    yves Renaudineau

  132. The contribution of epigenetics in Sjögren’s Syndrome

    Article • Frontiers in Genetics, April 2014, Frontiers

    yves Renaudineau

  133. Diagnostic criteria for autoimmune neutropenia

    Article • Autoimmunity Reviews, April 2014, Elsevier

    yves Renaudineau

  134. B cells display an abnormal distribution and an impaired suppressive function in patients with chronic antibody–mediated rejection

    Article • Kidney International, March 2014, Elsevier

    yves Renaudineau

  135. B1- and CD5-Positive B Cells

    Article • February 2014, Wiley

    yves Renaudineau

  136. A8.31 Characterisation of human transitional B-cells though their regulatory functions

    Article • Annals of the Rheumatic Diseases, January 2014, BMJ

    yves Renaudineau

  137. Diagnostic accuracy of blood B-cell subset profiling and autoimmunity markers in Sjögren’s syndrome

    Article • Arthritis Research & Therapy, January 2014, Springer Science + Business Media

    yves Renaudineau

  138. Glomerular Basement Membrane Autoantibodies

    Article • January 2014, Elsevier

    yves Renaudineau

  139. Level of agreement between 2002 American–European Consensus Group and 2012 American College of Rheumatology classification criteria for Sjögren’s syndrome and reasons for discrepancies

    Article • Arthritis Research & Therapy, January 2014, Springer Science + Business Media

    yves Renaudineau

  140. Lymphocytotoxic Autoantibodies

    Article • January 2014, Elsevier

    yves Renaudineau

  141. Épigénétique et auto-immunité

    Article • Revue Francophone des Laboratoires, December 2013, Elsevier

    yves Renaudineau

  142. DNA methylation modulates HRES1/p28 expression in B cells from patients with Lupus

    Article • Autoimmunity, October 2013, Taylor & Francis

    yves Renaudineau

  143. MicroRNAs and multiple sclerosis: from physiopathology toward therapy

    Article • Expert Opinion on Therapeutic Targets, September 2013, Informa Healthcare

    yves Renaudineau

  144. B-Lymphocyte Signalling Abnormalities and Lupus Immunopathology

    Article • International Reviews of Immunology, June 2013, Taylor & Francis

    yves Renaudineau

  145. Aberrant B-lymphocyte responses in lupus: inherent or induced and potential therapeutic targets

    Article • European Journal of Clinical Investigation, May 2013, Wiley

    yves Renaudineau

  146. Rationale for treating primary Sjögren’s syndrome patients with an anti-CD6 monoclonal antibody (Itolizumab)

    Article • Immunologic Research, April 2013, Springer Science + Business Media

    yves Renaudineau

  147. Epigenetic dysregulation in salivary glands from patients with primary Sjögren's syndrome may be ascribed to infiltrating B cells

    Article • Journal of Autoimmunity, March 2013, Elsevier

    yves Renaudineau

  148. A5.1 Abnormal Calcium Influx in T and B Lymphocytes from Systemic Lupus Erythematosus Patients is Related to STIM-1 Over-Expression

    Article • Annals of the Rheumatic Diseases, February 2013, BMJ

    yves Renaudineau

  149. A7.8 DNA Demethylation in Salivary Gland Epithelial Cells from Patients with Primary Sjögren’s Syndrome may be Ascribed to Infiltrating B Cells

    Article • Annals of the Rheumatic Diseases, February 2013, BMJ

    yves Renaudineau

  150. Homozygous FCGR3A-158F mutation is associated with delayed B-cell depletion following rituximab but with preserved efficacy in a patient with refractory lupus nephritis

    Article • Clinical Kidney Journal, December 2012, Oxford University Press (OUP)

    yves Renaudineau

  151. Serum markers of infections in patients with primary biliary cirrhosis: evidence of infection burden

    Article • Experimental and Molecular Pathology, December 2012, Elsevier

    Dr. Ori Barzilai, yves Renaudineau

  152. La présence d’anticorps anti-cellules HEK-293T caractérise les patients porteurs d’une glomérulonéphrite lupique active

    Article • Néphrologie & Thérapeutique, September 2012, Elsevier

    yves Renaudineau

  153. Altered patterns of epigenetic changes in systemic lupus erythematosus and auto-antibody production: Is there a link?

    Article • Journal of Autoimmunity, September 2012, Elsevier

    yves Renaudineau

  154. CD5 expression promotes multiple intracellular signaling pathways in B lymphocyte

    Article • Autoimmunity Reviews, September 2012, Elsevier

    yves Renaudineau

  155. Pierre Youinou: When intuition and determination meet autoimmunity

    Article • Journal of Autoimmunity, September 2012, Elsevier

    yves Renaudineau

  156. Epigenetics and Sjogren’s Syndrome

    Article • Current Pharmaceutical Biotechnology, July 2012, Bentham Science Publishers

    yves Renaudineau

  157. Mesangial Cell-Specific Antibodies Are Central to the Pathogenesis of Lupus Nephritis

    Article • Clinical and Developmental Immunology, January 2012, Wiley

    yves Renaudineau

  158. Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy

    Article • Annals of Hematology, November 2011, Springer Science + Business Media

    yves Renaudineau

  159. Anti-α actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1

    Article • Alimentary Pharmacology & Therapeutics, November 2011, Wiley

    yves Renaudineau

  160. Les auto-anticorps adoptent maintes combinaisons au cours de l’hépatite auto-immune…

    Article • Immuno-analyse & Biologie Spécialisée, October 2011, Elsevier

    yves Renaudineau

  161. Epigenetic alterations and autoimmune disease

    Article • Journal of Developmental Origins of Health and Disease, August 2011, Cambridge University Press

    yves Renaudineau

  162. Intérêt des anticorps anti-prothrombine et des anticorps anti-phosphatidylsérine/prothrombine dans le bilan d’une thrombose

    Article • Immuno-analyse & Biologie Spécialisée, August 2011, Elsevier

    yves Renaudineau

  163. Quel est l’intérêt de la recherche des anticorps anti-nucléolaires dans la sclérodermie systémique ?

    Article • Immuno-analyse & Biologie Spécialisée, August 2011, Elsevier

    yves Renaudineau

  164. Quels auto-anticorps pour le diagnostic et le suivi de la néphropathie lupique ?

    Article • Immuno-analyse & Biologie Spécialisée, June 2011, Elsevier

    yves Renaudineau

  165. Auto-anticorps anti-membrane basale glomérulaire et syndrome de Goodpasture

    Article • Immuno-analyse & Biologie Spécialisée, April 2011, Elsevier

    yves Renaudineau

  166. CD5 Promotes IL-10 Production in Chronic Lymphocytic Leukemia B Cells through STAT3 and NFAT2 Activation

    Article • The Journal of Immunology, March 2011, The American Association of Immunologists

    yves Renaudineau

  167. Les ANCA (typiques ou non) en pratique médicale courante

    Article • Immuno-analyse & Biologie Spécialisée, February 2011, Elsevier

    yves Renaudineau

  168. CD5 Expression in B Cells from Patients with Systemic Lupus Erythematosus

    Article • Critical Reviews™ in Immunology, January 2011, Begell House

    yves Renaudineau

  169. DNA Methylation and B-Cell Autoreactivity

    Article • January 2011, Springer Science + Business Media

    yves Renaudineau

  170. Epigenetics and Autoimmunity, with Special Emphasis on Methylation

    Article • The Keio Journal of Medicine, January 2011, Keio Journal of Medicine

    yves Renaudineau

  171. Aberrant expression of CD6 on B-cell subsets from patients with Sjögren’s syndrome

    Article • Journal of Autoimmunity, December 2010, Elsevier

    yves Renaudineau

  172. Epigenetics in autoimmune disorders: Highlights of the 10th Sjögren's Syndrome Symposium

    Article • Autoimmunity Reviews, July 2010, Elsevier

    yves Renaudineau

  173. The Fms-like tyrosine kinase 3 ligand, a mediator of B cell survival, is also a marker of lymphoma in primary Sjögren's syndrome

    Article • Arthritis & Rheumatism, June 2010, Wiley

    yves Renaudineau

  174. IVIg modulates BCR signaling through CD22 and promotes apoptosis in mature human B lymphocytes

    Article • Blood, June 2010, American Society of Hematology

    yves Renaudineau

  175. Epigenetics and autoimmunity

    Article • Journal of Autoimmunity, May 2010, Elsevier

    yves Renaudineau

  176. Glomerular Antibodies in Lupus Nephritis

    Article • Clinical Reviews in Allergy & Immunology, April 2010, Springer Science + Business Media

    yves Renaudineau

  177. Pharmacological role and clinical applications of interleukin-6 in rheumatoid disease

    Article • International Journal of Interferon Cytokine and Mediator Research, April 2010, Taylor & Francis

    yves Renaudineau

  178. 1093 ANTI-α ACTININ ANTIBODIES ARE INDEPENDENT PREDICTORS OF RESPONSE TO TREATMENT IN AUTOIMMUNE HEPATITIS TYPE 1

    Article • Journal of Hepatology, April 2010, Elsevier

    yves Renaudineau

  179. Endothelial dysfunction in systemic lupus patients with low disease activity: evaluation by quantification and characterization of circulating endothelial microparticles, role of anti-endothelial cell antibodies

    Article • Rheumatology, March 2010, Oxford University Press (OUP)

    yves Renaudineau

  180. Endogenous retrovirus control is impaired in B cells from patients with systemic lupus erythematosus

    Article • Annals of the Rheumatic Diseases, March 2010, BMJ

    yves Renaudineau

  181. NFAT2 and STAT3 control type 2 cytokines in CD5 B cells

    Article • Annals of the Rheumatic Diseases, March 2010, BMJ

    yves Renaudineau

  182. Rationale for Targeting CD6 as a Treatment for Autoimmune Diseases

    Article • Arthritis, February 2010, Hindawi Publishing Corporation

    yves Renaudineau

  183. A comprehensive evaluation of serum autoantibodies in primary biliary cirrhosis

    Article • Journal of Autoimmunity, February 2010, Elsevier

    Dr. Ori Barzilai, yves Renaudineau

  184. Conference Scene: Updating the Highlights of SjöGren‘s Syndrome

    Article • Immunotherapy, December 2009, Taylor & Francis

    yves Renaudineau

  185. Intérêt de la TEP au FDG dans les lymphomes folliculaires

    Article • Cancer/Radiothérapie, October 2009, Elsevier

    yves Renaudineau

  186. Monoclonal anti-CD20 antibodies: Mechanisms of action and monitoring of biological effects

    Article • Joint Bone Spine, October 2009, Elsevier

    yves Renaudineau

  187. Mécanismes de l’action des anticorps monoclonaux anti-CD20 et surveillance biologique de leurs effets

    Article • Revue du Rhumatisme, October 2009, Elsevier

    yves Renaudineau

  188. IL-10 Production by B Cells Expressing CD5 with the Alternative Exon 1B

    Article • Annals of the New York Academy of Sciences, September 2009, Wiley

    yves Renaudineau

  189. New ELISA for B Cell-Activating Factor

    Article • Clinical Chemistry, August 2009, AACC

    yves Renaudineau

  190. Autoreactive B Cells and Epigenetics

    Article • Clinical Reviews in Allergy & Immunology, July 2009, Springer Science + Business Media

    yves Renaudineau

  191. The Revolution of Epigenetics in the Field of Autoimmunity

    Article • Clinical Reviews in Allergy & Immunology, July 2009, Springer Science + Business Media

    yves Renaudineau

  192. B lymphocyte cytokines and rheumatic autoimmune disease

    Article • Arthritis & Rheumatism, July 2009, Wiley

    yves Renaudineau

  193. Which autoantibodies announce that lupus nephritis is on the way?

    Article • International Journal of Clinical Rheumatology, June 2009, OMICS Publishing Group

    yves Renaudineau

  194. IL-6 Modulates CD5 Expression in B Cells from Patients with Lupus by Regulating DNA Methylation

    Article • The Journal of Immunology, April 2009, The American Association of Immunologists

    yves Renaudineau

  195. Les maladies inflammatoires chroniques de l’intestin : quels autoanticorps choisir ?

    Article • Immuno-analyse & Biologie Spécialisée, February 2009, Elsevier

    yves Renaudineau

  196. Purine-Rich Box-1-Mediated Reduced Expression of CD20 Alters Rituximab-Induced Lysis of Chronic Lymphocytic Leukemia B Cells

    Article • Cancer Research, September 2008, American Association for Cancer Research (AACR)

    yves Renaudineau

  197. Selection of the Alternative Exon 1 from the cd5 Gene Down-Regulates Membrane Level of the Protein in B Lymphocytes

    Article • The Journal of Immunology, July 2008, The American Association of Immunologists

    yves Renaudineau

  198. Intérêt des nouveaux examens sérologiques pour la néphropathie lupique

    Article • Immuno-analyse & Biologie Spécialisée, June 2008, Elsevier

    yves Renaudineau

  199. Anti-α-Actinin Antibodies Cross-react with Anti-ssDNA Antibodies in Active Autoimmune Hepatitis

    Article • Clinical Reviews in Allergy & Immunology, January 2008, Springer Science + Business Media

    yves Renaudineau

  200. Renal Involvement in Wegener’s Granulomatosis

    Article • Clinical Reviews in Allergy & Immunology, January 2008, Springer Science + Business Media

    yves Renaudineau

  201. The paradox of CD5-expressing B cells in systemic lupus erythematosus

    Article • Autoimmunity Reviews, December 2007, Elsevier

    yves Renaudineau

  202. Anticorps anti-C1q et anticorps anti-α-actinine: nouveaux marqueurs de la glomérulonéphrite lupique

    Article • Revue du Rhumatisme, November 2007, Elsevier

    yves Renaudineau

  203. Anti-alpha-actinin antibodies: A new marker of lupus nephritis

    Article • Autoimmunity Reviews, August 2007, Elsevier

    yves Renaudineau

  204. Anticorps anti-α-actinine et anticorps anti-C1q: deux nouveaux «marqueurs» pour la glomérulonéphrite lupique

    Article • Immuno-analyse & Biologie Spécialisée, June 2007, Elsevier

    yves Renaudineau

  205. Apport des nouveaux examens biologiques au diagnostic de la polyarthrite rhumatoïde

    Article • Immuno-analyse & Biologie Spécialisée, June 2007, Elsevier

    yves Renaudineau

  206. CD5 links humoral autoimmunity with B-cell chronic lymphocytic leukemia

    Article • Expert Review of Clinical Immunology, May 2007, Taylor & Francis

    yves Renaudineau

  207. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of RITUXIMAB-TREATED patients with Sjögren's syndrome

    Article • Arthritis & Rheumatism, January 2007, Wiley

    yves Renaudineau

  208. Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20)

    Article • Arthritis & Rheumatism, January 2007, Wiley

    yves Renaudineau

  209. LYMPHOCYTOTOXIC AUTOANTIBODIES

    Article • January 2007, Elsevier

    yves Renaudineau

  210. Les anticorps anti-ADN ne sont plus ce qu'ils étaient!… L'apport des nouvelles techniques de dépistag e au diagnostic du lupus érythémateux disséminé

    Article • Revue Francophone des Laboratoires, November 2006, Elsevier

    yves Renaudineau

  211. Les nouveaux ANCA : leur mode d'emploi

    Article • Immuno-analyse & Biologie Spécialisée, October 2006, Elsevier

    yves Renaudineau

  212. Double Reactivity Against Actin and α-Actinin Defines a Severe Form of Autoimmune Hepatitis Type 1

    Article • Journal of Clinical Immunology, September 2006, Springer Science + Business Media

    yves Renaudineau

  213. Le pourquoi et le commentde l'auto-immunité

    Article • Revue Francophone des Laboratoires, July 2006, Elsevier

    yves Renaudineau

  214. Les nouveaux autoanticorps du syndrome de Gougerot-Sjögren primaire

    Article • Immuno-analyse & Biologie Spécialisée, June 2006, Elsevier

    yves Renaudineau

  215. B lymphocytes on the front line of autoimmunity

    Article • Autoimmunity Reviews, March 2006, Elsevier

    yves Renaudineau

  216. Endothelium, a target for immune-mediated assault in connective tissue disease

    Article • Autoimmunity Reviews, March 2006, Elsevier

    yves Renaudineau

  217. Association of α-actinin–binding anti–double-stranded DNA antibodies with lupus nephritis

    Article • Arthritis & Rheumatism, January 2006, Wiley

    yves Renaudineau

  218. An alternative exon 1 of the CD5 gene regulates CD5 expression in human B lymphocytes

    Article • Blood, October 2005, American Society of Hematology

    yves Renaudineau

  219. Characterization of the human CD5 endogenous retrovirus-E in B lymphocytes

    Article • Genes & Immunity, August 2005, Springer Science + Business Media

    yves Renaudineau

  220. B Lymphocytes Are Required for Development and Treatment of Autoimmune Diseases

    Article • Annals of the New York Academy of Sciences, June 2005, Wiley

    yves Renaudineau

  221. The Anti-Alpha-Actinin Test Completes Anti-DNA Determination in Systemic Lupus Erythematosus

    Article • Annals of the New York Academy of Sciences, June 2005, Wiley

    yves Renaudineau

  222. B Cell Response to Surface IgM Cross-Linking Identifies Different Prognostic Groups of B-Chronic Lymphocytic Leukemia Patients

    Article • The Journal of Immunology, March 2005, The American Association of Immunologists

    yves Renaudineau

  223. Rheumatoid factor on a daily basis

    Article • Autoimmunity, February 2005, Taylor & Francis

    yves Renaudineau

  224. Role of B-cell antigen receptor-associated molecules and lipid rafts in CD5-induced apoptosis of B CLL cells

    Article • Leukemia, December 2004, Springer Science + Business Media

    yves Renaudineau

  225. Les lymphocytes B réhabilités : leur rôle est déterminant dans la genèse de l'auto-immunité

    Article • Immuno-analyse & Biologie Spécialisée, December 2004, Elsevier

    yves Renaudineau

  226. Dysfunctional B cells in systemic lupus erythematosus

    Article • Autoimmunity Reviews, November 2004, Elsevier

    yves Renaudineau

  227. Requirement for B lymphocytes in autoimmunity development

    Article • Autoimmunity Reviews, November 2004, Elsevier

    yves Renaudineau

  228. Apport des examens sérologiques au diagnostic de la polyarthrite rhumatoïde : les leçons du suivi de 270 malades pendant trois ans

    Article • Immuno-analyse & Biologie Spécialisée, October 2004, Elsevier

    yves Renaudineau

  229. The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases

    Article • Thrombosis Research, January 2004, Elsevier

    yves Renaudineau

  230. Effects of Anti-Endothelial Cell Antibodies in Leprosy and Malaria

    Article • Infection and Immunity, January 2004, ASM Journals

    yves Renaudineau

  231. CD5-Expressing B Cells and Infection

    Article • January 2004, Elsevier

    yves Renaudineau

  232. CD5-Expressing B Cells and Infection

    Article • January 2004, Elsevier

    yves Renaudineau

  233. Endothelial Cell Autoreactivity and Infection

    Article • January 2004, Elsevier

    yves Renaudineau

  234. Endothelial Cell Autoreactivity and Infection

    Article • January 2004, Elsevier

    yves Renaudineau

  235. Recurrence of ANCA-positive glomerulonephritis immediately after renal transplantation

    Article • American Journal of Kidney Diseases, October 2003, Elsevier

    yves Renaudineau

  236. Antiendothelial cell antibodies in systemic lupus erythematosus

    Article • Autoimmunity Reviews, December 2002, Elsevier

    yves Renaudineau

  237. Autoantibodies to heparan sulfate proteoglycans

    Article • Autoimmunity Reviews, October 2002, Elsevier

    yves Renaudineau

  238. Consequences of Fcγ receptor type III reactivity in non-organ-specific autoimmune diseases

    Article • Biochemical Society Transactions, August 2002, Portland Press Ltd.

    yves Renaudineau

  239. Pathogenic effects of anti-Fc gamma receptor IIIb (CD16) on polymorphonuclear neutrophils in non-organ-specific autoimmune diseases

    Article • Autoimmunity Reviews, February 2002, Elsevier

    yves Renaudineau

  240. Cross-Linking of Human Fc RIIIb Induces the Production of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor by Polymorphonuclear Neutrophils

    Article • The Journal of Immunology, October 2001, The American Association of Immunologists

    yves Renaudineau

  241. Recent Progress in the Understanding of B-Cell Functions in Autoimmunity

    Article • Scandinavian Journal of Immunology, July 2001, Wiley

    yves Renaudineau

  242. Autoanticorps contre les polynucléaires neutrophiles au cours des maladies auto-immunes systémiques

    Article • La Revue de Médecine Interne, June 2001, Elsevier

    yves Renaudineau

  243. Functional heterogeneity of anti-endothelial cell antibodies

    Article • Clinical & Experimental Immunology, June 2001, Wiley

    yves Renaudineau

  244. Anti-Endothelial Cell Antibodies (AECA) in Systemic Sclerosis - Increased Sensitivity using Different Endothelial Cell Substrates and Association with Other Autoantibodies

    Article • Autoimmunity, January 2001, Taylor & Francis

    yves Renaudineau

  245. Characterization of murine monoclonal anti-endothelial cell antibodies (AECA) produced by idiotypic manipulation with human AECA

    Article • International Immunology, July 1998, Oxford University Press (OUP)

    yves Renaudineau

  246. Two populations of endothelial cell antibodies cross-react with heparin

    Article • Lupus, February 1998, SAGE Publications

    yves Renaudineau